Recently, the cocktail CD19/22 CAR-T cell therapies improved the outcome of aggressive B-cell lymphoma with 72.2% ORR and 50% CR rate, in which the CAR-T cells with different targets contributed to enhanced antitumor effects (13), while there were mainly DLBCL patients and few BL patients enrolled. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.